Finanzen von Larimar Therapeutics Inc (LRMR)LRMRLarimar Therapeutics Inc

Evaluating the bottom line, Larimar Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -139.63%, provide a clear picture of how effectively LRMR converts its operational activities into shareholder value.

In the context of the broader market, LRMR competes directly with industry leaders such as RCKT and GALT. With a market capitalization of $452.93M, it holds a leading position in the sector. When comparing efficiency, LRMR's gross margin of N/A stands against RCKT's N/A and GALT's N/A. Such benchmarking helps identify whether Larimar Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Larimar has shown a significant decline in net income, with losses increasing to -$32.78 million in Q2 2026. The current ratio remains strong at 4.70, indicating good short-term financial health despite the losses.